Sandbox Rim: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) No edit summary |
Rim Halaby (talk | contribs) |
||
Line 1: | Line 1: | ||
==Treatment of Acute Decompensation of Heart Failure== | ==Treatment of Acute Decompensation of Heart Failure== | ||
'''Initial stabilization:''' <br> | '''Initial stabilization:''' <br> | ||
* Assess the airway | |||
* Position the patient upright at an angle of 45 degrees, with legs dangling off the bedside | |||
* Check pulse oximetry | |||
* If hypoxemia is present (Sa02 < 90% or Pa02 <60 mmHg), administer oxygen with/without noninvasive ventilation | |||
* Avoid IV morphine (may increase mortality / duration of intubation, generally not advisable, may relieve refractory symptoms) | |||
* Ensure continuous cardiac monitoring | |||
* Secure intravenous access with 18 gauge canula | |||
* Monitor vitals signs | |||
* Monitor fluid intake and urine output | |||
'''Assess congestion and perfusion:'''<br> | |||
❑ Congestion at rest (dry vs. wet)<br> | |||
''"Wet" suggested by orthopnea, ↑JVP, rales, S3, pedal edema'' | |||
'' | ❑ Low perfusion at rest (warm vs. cold)<br> | ||
''"Cold" suggested by narrow pulse pressure, cool extremities, hypotension'' | |||
* Warm and dry | * Warm and dry | ||
* Warm and wet | * Warm and wet | ||
* Cold and dry | * Cold and dry | ||
* Cold and wet | * Cold and wet | ||
'''Admit for in-hospital treatment if:''' <br> | '''Admit for in-hospital treatment if:''' <br> | ||
* Hypotension and/or cardiogenic shock | |||
* Poor end-organ perfusion (worsening renal function, cold clammy extremities, altered mental status) | |||
* Hypoxemia (Sa02 <90%) | |||
* Atrial fibrillation with a rapid ventricular response resulting in hypotension | |||
* Presence of an underlying condition, such as acute coronary syndrome | |||
'''Identify precipitating factor and treat accordingly:''' <br> | '''Identify precipitating factor and treat accordingly:''' <br> | ||
Line 27: | Line 40: | ||
* Drugs (NSAIDS, thiazides, calcium channel blocker, beta blockers) | * Drugs (NSAIDS, thiazides, calcium channel blocker, beta blockers) | ||
* Toxins (alcohol, anthracyclines) | * Toxins (alcohol, anthracyclines) | ||
* | * Atrial fibrillation | ||
: ''Rate control of atrial fibrillation is the mainstay of arrhythmia therapy. Avoid the use of drugs with negative inotropic effects such as beta blockers and non-dihydropyridine calcium channel blockers e.g., verapamil in the treatment of acute decompensated systolic heart failure'' | |||
: ''Consider cardioversion if the patient is in cardiogenic shock or if new onset atrial fibrillation is the clear precipitant of the hemodynamic decompensation'' | |||
* COPD | * COPD | ||
* PE | * PE |
Revision as of 18:54, 12 March 2015
Treatment of Acute Decompensation of Heart Failure
Initial stabilization:
- Assess the airway
- Position the patient upright at an angle of 45 degrees, with legs dangling off the bedside
- Check pulse oximetry
- If hypoxemia is present (Sa02 < 90% or Pa02 <60 mmHg), administer oxygen with/without noninvasive ventilation
- Avoid IV morphine (may increase mortality / duration of intubation, generally not advisable, may relieve refractory symptoms)
- Ensure continuous cardiac monitoring
- Secure intravenous access with 18 gauge canula
- Monitor vitals signs
- Monitor fluid intake and urine output
Assess congestion and perfusion:
❑ Congestion at rest (dry vs. wet)
"Wet" suggested by orthopnea, ↑JVP, rales, S3, pedal edema
❑ Low perfusion at rest (warm vs. cold)
"Cold" suggested by narrow pulse pressure, cool extremities, hypotension
- Warm and dry
- Warm and wet
- Cold and dry
- Cold and wet
Admit for in-hospital treatment if:
- Hypotension and/or cardiogenic shock
- Poor end-organ perfusion (worsening renal function, cold clammy extremities, altered mental status)
- Hypoxemia (Sa02 <90%)
- Atrial fibrillation with a rapid ventricular response resulting in hypotension
- Presence of an underlying condition, such as acute coronary syndrome
Identify precipitating factor and treat accordingly:
- Myocardial infarction
- Myocarditis
- Renal failure
- Hypertensive crisis
- Non adherence to medications
- Worsening aortic stenosis
- Drugs (NSAIDS, thiazides, calcium channel blocker, beta blockers)
- Toxins (alcohol, anthracyclines)
- Atrial fibrillation
- Rate control of atrial fibrillation is the mainstay of arrhythmia therapy. Avoid the use of drugs with negative inotropic effects such as beta blockers and non-dihydropyridine calcium channel blockers e.g., verapamil in the treatment of acute decompensated systolic heart failure
- Consider cardioversion if the patient is in cardiogenic shock or if new onset atrial fibrillation is the clear precipitant of the hemodynamic decompensation
- COPD
- PE
- Anemia
- Thyroid abnormalities
- Systemic infection
Treat congestion and optimize volume status:
Diuretics
- IV loop diuretics as intermittent boluses or continuous infusion (I-B)
- Already on loop diuretics: IV dose >= home PO dose (I-B)
- Serial assessment of fluid intake and output, vital signs, body weight (measured every day at the same time) and symptoms
- Adjust dose according to volume status (I-B)
- Daily electrolytes, BUN, creatinine (I-C)
- Persistent symptoms: Increase dose of IV loop diuretics (I-B) OR Add a second diuretics, such as thiazide (I-B)
- Consider low dose dopamine infusion for improved diuresis and renal blood flow (IIb-B)
- Consider renal replacement therapy/Ultrafiltration in obvious volume overload (IIb-B)
Venodilators
- Consider IV nitroglycerin, nitroprusside, or nesiritide as add-on to diuretics to relieve dyspnea (IIb-A)
Treat low perfusion:
- Inotropes
VTE prevention:
- Anticoagulation in the absence of contraindications (I-B)
Chronic medical therapy:
- Chronic HFrEF and hemodynamically stable: continue medical therapy
- Initiate beat blockers at a low dose in stable patients following optimization of volume status and D/C IV diuretics and inotropes (I-B)
Management of hyponatremia:
- Water restriction
- Optimization of chronic home medications
- Persistent hyponatremia and risk of cognitive impairment: vasopressin antagonist for short term (hypervolemic)